Whitehawk

1 known investors

WhiteHawk develops antibody drug conjugates (ADCs) for cancer treatment, using an ADC platform engineered for high therapeutic index and stability combined with tumor targeting. Its pipeline includes three oncology assets targeting clinically validated proteins, with an initial focus on lung and gynecological cancers.